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We have synthesized and characterized gold nanoparticles (spheres and rods) with optical extinction bands within the “optical
imagingwindow.”Theintenseplasmonresonantdrivenabsorptionandscatteringpeaksofthesenanoparticlesmakethemsuitable
as contrast agents for optical imaging techniques. Further, we have conjugated these gold nanoparticles to a mouse monoclonal
antibody speciﬁc to HER2 overexpressing SKBR3 breast carcinoma cells. The bioconjugation protocol uses noncovalent modes of
binding based on a combination of electrostatic and hydrophobic interactions of the antibody and the gold surface. We discuss
various aspects of the synthesis and bioconjugation protocols and the characterization results of the functionalized nanoparticles.
Some proposed applications of these potential molecular probes in the ﬁeld of biomedical imaging are also discussed.
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1. INTRODUCTION
Optical imaging encompasses a multitude of techniques for
the elucidation of morphology, molecular function, and
metabolism of tissue with the general objective of detecting,
diagnosing, staging, and treatment monitoring of disease.
Progression of disease is usually accompanied by changes in
physiology and pathology that are manifested as location-
speciﬁc changes in optical properties thereby providing con-
trast for optical imaging to study disease.
Optical imaging techniques span the range from surface
to bulk imaging systems with applications ranging from “op-
tical biopsies” to full human breast imaging with resolutions
that cover the microscopic to macroscopic. Some important
imaging techniques for superﬁcial tissue imaging are confo-
cal microscopy [1], two-photon microscopy [2], and opti-
cal coherence tomography (OCT) [3]. Techniques that per-
mit subsurface to deep imaging are diﬀuse optical imaging
(DOT) [4] and photoacoustic imaging [5].
The interaction of visible and near-infrared (NIR) light
with tissue is dominated by
(a) absorption processes which are due to the presence
o fv a r i o u sc h r o m o p h o r e ss u c ha sh e m o g l o b i n ,o x y -
hemoglobin, melanin, water, and lipids [6];
(b) scattering processes due to the cell membrane and cell
structures such as the nucleus, mitochondria, lyso-
somes [6].
Penetration of light in tissue is dependent on the extent
of the two processes above and is low in the high-energy vis-
ible region of the spectrum. This is due to high absorption
by hemoglobin and severe light scattering. In the wavelength
regime between 600nm and 1100nm, absorption and scat-
tering losses are minimal permitting high-light penetration.
This is the so-called “optical imaging window” which is ex-
ploited for deep imaging in tissue [7].
The sensitivity and speciﬁcity of optical imaging tech-
niques to visualize a pathological disorder are governed by
contrast: the ability of the disease to diﬀerentially scatter or
absorblightcomparedwithnonpathologicaltissueandback-
groundnoise.Thisnativeorendogenouscontrastmaynotbe
suﬃcient and in any case, the interactions of light with tissue2 International Journal of Biomedical Imaging
are not disease-speciﬁc. Therefore, there is a role for exoge-
nously administered contrast enhancing agents which have
aﬃnity for the disease site through biochemical interactions,
providing not only sensitive but also disease-speciﬁc signals.
Contrast agents for optical imaging thus far have near-
infrared dyes based on cyanine dyes [8] such as Indocyanine
Green [9], but in the last few years, gold nanoparticles [10–
12] have emerged as prime candidates due to their unusual
optical properties and inherent biocompatibility.
Gold metal nanoparticles (NPs) exhibit narrow and in-
tense absorption and scattering bands due to the phe-
nomenon of plasmon resonance. This occurs at the reso-
nance condition of the collective oscillation that the conduc-
tion electrons experience in an electromagnetic ﬁeld of the
appropriate wavelength [13]. The plasmon resonant condi-
tion of gold NPs depends upon their size, shape, structure
(solid or hollow), and upon the refractive index of the em-
bedding medium. Spherical gold nanoparticles have a single
plasmon resonant extinction peak at around 520nm, which
does not shift extensively with changes in size and refractive-
index of the surrounding medium. This is a wavelength at
whichlightpenetrationintissueispoorduetostrongscatter-
ingandabsorptionbyhemoglobin,andgoldnanospheresare
not useful in contrast enhancement for deep tissue imaging.
Rod-shaped NPs exhibit two plasmon resonances due to
oscillation of the conduction electrons along the short axis as
well as along the long axis of the particles. The former plas-
monbandiscalledthetransverseresonanceandthelatterthe
longitudinal resonance. While the transverse plasmon band
occursintheneighborhoodof520nm,thelongitudinalband
is red-shifted. The extent of the red-shift depends on the as-
pect ratio of the nanorod; the higher the aspect ratio, the fur-
ther the shift. Thus by tailoring the length and/or width of
these particles, their extinction peaks may be made to cover
the low-energy visible to infrared wavelength regions.
The intense scattering and absorption of light, that oc-
curs under the plasmon resonant condition coupled with the
ability to tune the resonance into the near-infrared (NIR)
by manipulating the aspect ratio, make gold nanorods ex-
tremelyattractiveas contrastagentsfor optical imaging tech-
niques. Further, gold-protein chemistry is well developed
and several bioconjugation protocols are available in the lit-
erature, which allows the combination of the targeting func-
tionality of antibodies with such gold NPs. The inertness and
biocompatibility of gold in general hold promise the use of
gold NPs for in vivo imaging applications.
Gold NPs can be synthesized using wet chemical meth-
ods which are based on the reduction of gold salts by
reagents such as sodium borohydride and ascorbic acid.
Seed-mediated methods dominate wet chemical synthesis
routes. These involve the reduction of gold using weak
reducing agents onto small nanospheres of gold as seed,
in the presence of shape-directing surfactants usually cetyl
trimethylammonium bromide (CTAB). These methods may
be distinguished into those that use silver ion assistance in
growth solutions and those that do not.
Murphy and coworkers described the three-step growth
protocol [14, 15], where medium to high aspect ratio
nanorods could be synthesized, without the use of silver ni-
trate. Seed particles are generated by reducing gold salt us-
ing sodium borohydride in the presence of sodium citrate.
The spheres are coated with a layer of negatively charged
citrate ions that maintain colloid stability against aggrega-
tion by electrostatic repulsion. These spheres seed a growth
solution comprising gold salt, CTAB, and ascorbic acid in
three steps thereby slowing down reduction. The mechanism
of nanorod formation by this method is not yet fully un-
derstood. Murphy et al. [15] proposed that the polar CTA+
head group of the surfactant binds with greater preference
to certain crystallographic faces thereby passivating them to
the deposition of gold. The other faces, on the other hand,
would be exposed for gold to be reduced on, thereby pro-
ducing anisotropic growth into rods.
The methods using silver nitrate in the growth solu-
tions were proposed by Jana et al. [16], but modiﬁed by
Nikoobakht and El-Sayed [17] to achieve spectacular yields
of nanorods with excellent monodispersity. Importantly,
they also showed that changing the quantity of Ag+ ions in
thegrowthsolutionallowsforﬁne-tuningoftheaspectratios
of the nanorods. The mechanism at work in this protocol has
been debated in the recent past. One mechanism postulates
CTAB as a soft template which elongates on addition of Ag+
ions which occupy regions between the CTA+ head groups to
reducetherepulsionbetween theheadgroups[17].Asecond
mechanism invokes the CTAB passivation concept with ad-
ditional adsorption of silver bromide on facets slowing down
reductionandproducingrodsshorterthanthosemadewith-
out using Ag+ [18]. A third mechanism which has appeared
recently [19] proposes the underpotential deposition of Ag0
on certain faces, followed by CTAB binding, which serves to
stabilize the faces, and allows gold reduction on other faces
resulting in rod formation.
In this article, we present our experiences in synthesiz-
ing gold nanospheres and nanorods using slight modiﬁca-
tions of the protocols discussed above. Our goal is to obtain
nanorods whose aspect ratios can be tuned to obtain plas-
mon peaks between 650nm–850nm. Next, we conjugate the
gold nanospheres and gold nanorods to the HER81 mono-
clonal antibody using electrostatic and hydrophobic interac-
tions. The conjugation does not use modiﬁcations of the bi-
layer charge of nanorods nor does it use any linkers. We dis-
cuss various aspects of these protocols and postulate a possi-
ble mechanism for the bioconjugation of the antibody with
the gold nanorods. We also discuss the feasibility of using
these molecular probes for contrast enhancement of photoa-
coustic cancer imaging using simulations.
2. EXPERIMENTAL SECTION:
MATERIALS AND METHODS
2.1. Goldnanorodsusingthesilver-assistedsingle
surfactantgrowthmethod
As mentioned earlier, the seed-mediated protocol requires
the use of small gold nanospheres to seed growth solutions
with silver nitrate as per the protocol of Nikoobakht and El-
Sayed [17].Raja Gopal Rayavarapu et al. 3
Table 1: Mean aspect ratios, lengths, widths, and longitudinal plasmon peaks for nanorods synthesized using the silver-assisted growth
method.
Sample Volume of AgNO3 ( μL) Aspect ratio (R) Length (nm) Width (nm) LP band (nm)
15 0 2 .3 ±0.34 4 .8 ± 4.11 9 .8 ±2.9 675
2 100 2.85 ±0.64 5 .1 ± 5.51 5 .8 ±3.1 764
3 150 3.0 ±0.64 1 .7 ± 3.91 3 .9 ±2.3 788
4 200 3.1 ±0.55 2 .0 ± 4.61 6 .8 ±2.8 831
5 250 3.6 ±0.65 1 .0 ± 4.41 4 .1 ±2.1 850
The following are the reagents used for the synthesis of
the gold seed and gold nanorods.
Tetrachloroauric acid (HAuCl4 · 3H2O) was purchased
from Acros Organics (Belgium), hexadecyltrimethylam-
monium bromide (CTAB > 99%), sodium borohydride
(NaBH4, 99%), and ascorbic acid (99%) from Aldrich (The
Netherlands) and silver nitrate (AgNO3, 99.8%) from Merck
(Germany). Prior to use, all glassware was cleaned with hy-
droﬂuoric acid (HF), further with aqua regia (HCl/HNO3)
and rinsed twice with deionized water.
Goldseedof3.5nmdiameter
The synthesis was done using protocols of Nikoobakht and
El-Sayed [17] with slight modiﬁcations. A solution of CTAB
(5mL; 0.2M) was sonicated for 20 minutes at 40◦Ci naw a -
ter bath. A solution of HAuCl4 ·3H2O (5mL; 0.0005M) was
added with continuous stirring under inert conditions (ni-
trogen environment). Then, an ice-cold aqueous solution of
NaBH4 (0.6mL; 0.01M) was added at once with vigorous
stirring for 1 minute. This seed solution (CTAB-capped) is
further used during growth stage of nanorods.
Goldnanorodsofvaryingaspectratios
Five identical conical ﬂasks containing 10mL of a growth so-
lution that consists of CTAB (5mL; 0.2M) and HAuCl4·
3H2O (5mL; 0.001M) were prepared. The color of the
growth solution is dark-yellow. AgNO3 (50, 100, 150, 200,
and250μLof0.006M)wasaddedtotheﬁveidenticalgrowth
solution ﬂasks in an amount that was chosen so as to yield
desired aspect ratios for the resulting nanorods. Following
this, the mild reducing agent ascorbic acid (70μL; 0.1M)
was added to each growth solution conical ﬂask to give col-
orless solutions. Finally, 14μL of preformed CTAB-capped
seed solution was added to each conical ﬂask, and mixtures
were gently mixed. After 3 hours at 24◦C, the nanorod sus-
pension turned into a dark-blue solution with a brownish
opalescence.Thesesolutionswereconcentratedbycentrifug-
ing twice at 12000g for 20 minutes which also enabled re-
moval of the excess unbound CTAB. The centrifuged gold
nanorods which are dispersed in water were stored at 4◦C.
2.2. Characterizationofgoldnanoparticles
Electron microscopy of the NPs was performed using a
CM 30 Philips transmission electron microscope (TEM) or
a Zeiss-1550 high-resolution scanning electron microscope
(HRSEM). Particle sizes were estimated using NI Vision
module (Labview, National Instruments) on the digital SEM
images with at least 250 particles considered in each case. Ex-
tinction spectra of NPs (and bioconjugated NPs) were mea-
sured using the Shimadzu PC3101 UV-Vis-NIR spectropho-
tometer.
The concentration of nanorods synthesized was esti-
mated using the relation A = cdε,w h e r eA is the measured
absorbance, c the concentration in moles (M), ε the molar
extinction coeﬃcient (M−1cm−1), and d the path length of
the cuvette used to record the spectra. The derived molar ex-
tinctioncoeﬃcientscanbecomparedwithε valuesfromare-
centreport,estimatedforarangeofaspectratiosofnanorods
by measuring the gold content in sols using inductively cou-
pled plasma (ICP) atomic emission spectroscopy [19].
2.3. BioconjugationofHER81mAbto
goldnanoparticles
Conjugation was achieved using combination of electrostatic
and hydrophobic binding interactions. The particles chosen
for bioconjugation were 25nm citrate-capped gold spheres
(Aurion, Wageningen, The Netherlands), and silver-assisted
surfactant mediated gold nanorods with aspect ratios of ap-
proximately 2.85 (see Table 1) with the longitudinal plasmon
peakat764nm.Theanti-HER2mousemonoclonalantibody
(mAb) (Immunicon, USA) was chosen as the targeting moi-
ety. The antibody designated as HER81 recognizes Human
EGF receptor 2, HER2. HER2, also called erbB2, is a member
of the epidermal growth factor receptor (EGFR) family and
is overexpressed in 20–40% of human breast cancers [20].
In general, for optimum conjugation, it is recommended
that the pH of the antibody and gold sol be maintained at or
slightly higher than the isoelectric point (pI) of the antibody
[21]. The isoelectric (pI) point of HER81 mAb was deter-
mined using the Pharmacia PhastSystem isoelectric focusing
(IEF). The pH of the antibody was adjusted with dialysis in
5mM sodium acetate buﬀer and the pH of the colloidal gold
was adjusted with 0.1M KOH, to approximately 0.5pH units
above this value.
Next, the minimum protecting amount of antibody to be
usedfortheconjugationisdetermined.Thisistheamountof
protein that is required to maintain colloidal stability of the
conjugatedNPsuponadditionofNaCl[21]asj udgedb yc ol-
orimetric analysis; as long as the conjugated NPs turns blue,
particle aggregation takes place implying that the amount of
protein is not suﬃcient to stabilize the suspension. By trial,
diﬀerent amounts of antibody are added to samples of the4 International Journal of Biomedical Imaging
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Figure 1:Opticalextinctionspectrumofpreformed8-minute-aged
CTAB-capped gold nanospheres as seed for nanorod synthesis.
gold sol, gently mixed, and allowed to stand at room tem-
perature for 2 minutes. Spectroscopic analysis reveals which
sample remains stable; the minimum amount of protein
added is then ascertained and is used for subsequent con-
jugation of the gold sol.
To block the free surfaces on the gold, 10% bovine serum
albumin (BSA) in dialyzed buﬀer (sodium acetate), main-
tained at the same pH as the antibody solution, is used. The
BSA was added to the conjugate to a ﬁnal concentration of
1% and was allowed to incubate for 5 minutes. The resultant
was then centrifuged for 30 minutes at 12000g to remove
excess protein and incompletely stabilized particles. The re-
sulting pellet is dispersed in phosphate buﬀered saline (PBS)
containing 1% BSA and stored at 4◦C.
2.4. Cellcultureandcell-bioconjugateincubation
The HER2 positive mammary adenocarcinoma (SKBR3) cell
line was used as a positive cell line; Chinese hamster ovary
(CHO)cellswereusedasanHER2negativecellline.Thecells
were cultured in RPMI 1640 medium (Invitrogen) supple-
mented with glutamine, 10% FBS (Fetal Bovine Serum) with
antibiotics. Cells were maintained in an incubator at 37◦C
and 5% CO2.
The cells were detached from the tissue culture plate us-
ing trypsin. The cells were replated onto 12mm glass cover
slips in a 6-well tissue culture plate, and allowed to grow for
2d a y sa t3 7 ◦C, 5% CO2. When the cells grew to 80% con-
ﬂuence on the cover slips, the cells were rinsed with phos-
phate buﬀered saline (PBS) and ﬁxed in 4% paraformalde-
hyde (PFA) for 15 minutes at room temperature.
2.5. Immunostainingandconfocalmicroscopy
After ﬁxation, immunostaining was performed on the cells.
The cells were incubated with 100μLo fc o n j u g a t e dg o l d
nanoparticles at a concentration of 9.7 × 1010 particles per
mL for 2 hours followed by silver enhancement performed
using a silver-staining kit (Aurion, Wageningen, The Nether-
lands).
Confocal microscopy reﬂection images of the cells on
cover slips were recorded on a Zeiss LSM 510 confocal laser
scanning microscope using a C-Apochromat 63 X/1.4 nu-
merical aperture (NA) water-immersion objective. An exci-
tation wavelength of 543nm was chosen and reﬂection im-
ages recorded using a 500–550nm bandpass ﬁlter. All images
were acquired with pinhole diameters of 178μm. Care was
taken to ensure that the excitation intensity as well as detec-
tor and ampliﬁer gains were maintained at the same values
for all images to facilitate comparison.
3. RESULTS
3.1. Synthesisofgoldnanorods
We used seed particles within about 8 minutes of formation
in the subsequent growth phase. The optical extinction spec-
trum of 8-minute-aged seed is shown in Figure 1.
Figure 2 shows the extinction spectrum and HR-SEM
image of the nanorods synthesized using 50μLA g N O 3 in
the growth solution. The peak at 675nm can be attributed
to longitudinal plasmon resonance and the peak in the vicin-
ity of 516.5nm to transverse plasmon resonance.
Examination of the SEM image and determination of
the mean sizes conﬁrm that the NPs produced consist of
monodisperse nanorods of aspect ratio of 2.3 ± 0.3, with a
smallnumberoflargespheres;thelatter’sextinctionpeakco-
inciding with the transverse plasmon band of the nanorods.
Figure 3 shows the extinction spectrum and the SEM image
for the sample produced using 250μL of silver nitrate. It is
seenthatthelongitudinalplasmonbandisshiftedto850nm.
Sizing from the SEM image yields an average aspect ratio of
3.6 ± 0.6. Figure 4 shows the size distribution of the 2 speci-
mens.
The values of the molar extinction coeﬃcient for the 2
casesaboveare3.3±0.3×109 and5.5±0.3×109 M−1cm−1 ob-
tained by extrapolation of the data as reported in [19]. With
this,wearriveattheconcentrationofthenanorodswithpeak
at 675nm as 4.3 ± 0.3 × 1011 NR/mL; for nanorods with the
peak at 850nm as 1.3 ±0.7 ×1011 NR/mL.
Figure 5 shows the consolidated normalized extinction
spectra of 5 nanorod solutions, having identical growth so-
lutions with varying silver nitrate volumes. The spectra were
normalized to the peak at 516nm, which is due to a combi-
nation of the transverse plasmon resonance of the nanorods
and the signature peak of gold nanospheres. It is seen that
with higher silver nitrate volumes the extent of red-shifting
increases [22]. The details of the observed changes in aspect
ratios and plasmon bands are presented in Table 1.
3.2. Bioconjugationofgoldnanospheres
andgoldnanorods
A signature for successful binding of protein to gold NPs is
a red-shifted and amplitude reduced plasmon band. BothRaja Gopal Rayavarapu et al. 5
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Figure 2: Gold nanorods synthesized using50μL ofsilver nitratein growth solution. (a)Optical extinction spectrum showingthetransverse
plasmon peak at 516.5nm and the longitudinal plasmon peak at 675nm. The amplitude of the longitudinal plasmon peak is higher than
transverseplasmonpeakwhichindicatestheformationofhighyieldofnanorodscomparedtospheres.(b)High-resolutionscanningelectron
microscope (SEM) image of gold nanorods showing high monodispersity. Few nanospheres are observed.
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Figure3:Goldnanorodssynthesizedusing250μLofsilvernitrateingrowthsolution.(a)Opticalextinctionspectrumshowingthetransverse
plasmon peak at 516nm and the longitudinal plasmon peak at 850nm. (b) High-resolution scanning electron microscope (SEM) image.
these eﬀects are due to the formation of the inhomogeneous
layer of protein on the gold particle surface that leads to the
modiﬁcation of refractive index of the embedding medium.
Figure 6(a) shows the extinction spectrum of gold
nanospheres before and after incubation with HER81.
Figure 6(b) is the corresponding situation with gold
nanorods before and after incubation with the HER81 mAb.
In both cases, the characteristic red-shift in the extinction
peak of the plasmon bands is seen.
Not too much should be read into the amplitude changes
oftheextinctionspectrasincecentrifugationofthebioconju-
gate to remove unbound protein, redispersion in water, and
other procedures results in a change in the concentration of
the NPs used for spectroscopy.
Figure 7(a) show confocal reﬂectance image (on left) and
bright ﬁeld image (on right) of the HER81 mAb/gold sphere
conjugates incubated with SKBR3 cells. As discussed in the
experimental section, silver enhancement was used by which
silver is reduced onto the gold particles forming large clus-
ters around 500nm in size. This then enables visualization
under the microscope. The HER2 receptors are localized to
the cell membranes of SKBR3 cells. The high intensities in
both images at the cell membrane are then evidence of the
preservation of the functionality of the antibody and also il-
lustrate successful conjugation. The images in Figure 7(b),
which show the situation with the negative control using the
CHO cells, display no such accumulation of gold particles.
Also,addingnonantibodyconjugatedgoldNPstotheSKBR36 International Journal of Biomedical Imaging
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cells did not result in accumulation of the nanorods, indicat-
ingthespeciﬁcityoftheHER81antibody-nanorodconjugate
(data not shown).
Figures 8(a) and 8(b) are the results of the corresponding
controls using the HER81 mAb/gold nanorods.
4. DISCUSSION
4.1. Goldnanorodsynthesis
The end products of the seed-mediated growth protocols are
crucially dependent on the nature of the seed, upon their
sizeanduponthecappingagentsused.Additionally,thecon-
stituents and their concentrations in the growth solution in-
ﬂuence the outcome of the synthesis products. The addition
ofsilverionsinthegrowthsolutionandtheuseofpreformed
CTAB stabilized seed in the protocol of Nikoobakht and
El-Sayed [17] produced not only a high yield of monodis-
perse nanorods but ﬁne tunability of aspect ratios.
There are many unanswered questions regarding the
mechanism of formation of gold nanorods using the silver-
assistedprotocolandthishasbeenthetopicofseveralstudies
[15, 17–19]. Recent reports of Orendorﬀ and Murphy [19],
and Liu and Guyot-Sionnest [23] provide some insights into
the mechanisms that could be involved in the synthesis. It is
postulated that silver ions are reduced by ascorbic acid even
though it is a weak reducing agent, by the phenomenon of
underpotential deposition (UPD). This is reduction of sil-
ver in monolayers on the growing gold nanorod surface at
a potential less than the standard reduction potential [19].
The deposition is not uniform on the gold surface but occurs
faster on the sidewalls compared with the end faces. Remark-
ably, the sidewalls in the case of nanorods produced with sil-
verassistanceusingCTABprotectedseedbearAu{110}faces,
while the end faces have Au{100} faces. This is in contrast to
the rods prepared by using citrate-capped seed without Ag+.
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This faster passivation of the sidewalls is followed by CTAB
binding possibly via bromide ions. This inhibits the reduc-
tion of gold, which deposits on the end faces. Ultimately,
the end faces are also stabilized preventing the formation of
very long nanorods. The model claims also to explain the in-
crease in aspect ratio of the nanorods produced with higher
concentration of silver ions used, by proposing that higher
UPD of silver monolayers occur on the sidewalls which one
assumes reducing the width of the nanorods thus increasing
the aspect ratios [19].Raja Gopal Rayavarapu et al. 7
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Figure 6: Extinction spectra before and after incubation of HER81 with (a) gold nanospheres, (b) gold nanorods. In both cases, a red shift
in plasmon band(s) occurs after incubation with the antibody signifying successful bioconjugation.
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Figure 7: Confocal reﬂectance images (left) and bright ﬁeld images (right) of (a) SKBR3 cells incubated with silver-stained HER81/gold
sphere conjugates, (b) CHO cells under the same conditions. Care was taken to maintain the same acquisition parameters in both cases. The
silver-stained bioconjugates are detected at the cell membranes of SKBR3 cells where HER2 is localized. This indicates successful conjugation
and retention of functionality of the antibody after conjugation. No such accumulation of HER81/gold sphere conjugates is demonstrated
in HER2 negative CHO cells.
Indeed, we observe some phenomena that are consis-
tent with the above model. We are able to synthesize gold
nanorods only up to an aspect ratio of 3.6, as shown in
Figure 3. Addition of higher volumes of silver nitrate pro-
duces no further increase in the aspect ratios of the particles.
These particles have an average length of 51nm. This sup-
ports the idea that ultimately complete passivation of the en-
tire nanorod surface occurs preventing further gold deposi-
tion even though the reagents have not been exhausted. Fur-
ther, we observe that nanorods that are made with increasing
Ag+ volumes have smaller diameters with the lengths practi-
cally unchanged or only slightly increasing (see Table 1). The
above model can also explain this. It must be mentioned that
the model does not have an appealing explanation regarding
the ability to tune the aspect ratios so precisely by Ag+ vari-
ation. It is very likely that the model will have to undergo
reﬁnements or even major changes before it is universally ac-
cepted.
4.2. Goldnanoparticle—antibodyconjugation
The noncovalent conjugation of proteins to colloidal gold
is usually due to a combination of electrostatic and hy-
drophobic interactions. Citrate-capped gold NPs are nega-
tivelychargedduetoalayerofnegativecitrateions.Positively
chargedaminogroupsoftheantibodywillbeattractedtothe8 International Journal of Biomedical Imaging
(a) (b)
Figure 8: Corresponding images as in Figure 7 for bioconjugates consisting of silver-stained HER81/gold nanorod conjugates incubated
with (a) SKBR3 cells and (b) CHO cells. Care was taken to maintain the same acquisition parameters in both cases. The bioconjugates are
accumulated at the cell membranes of SKBR3 cells where HER2 is localized. As expected, no such accumulation takes place in the case of
HER2 negative CHO cells.
Table 2: Important optical imaging techniques that utilize absorption and scattering contrasts in biology and medicine.
Technique Imaging depth Imaging resolution Mechanism Typical imaging applications
Confocal microscopy [1] 500μm > 250nm Scattering /absorption Tissue surfaces
Two-photon microscopy [2] 800μm > 250nm Absorption Tissue surfaces
Optical coherence
tomography [3]
2mm 1μm Scattering Surfaces/subsurfaces
of tissue
Diﬀuse optical tomography [4] > 20mm ≈ 10% depth Scattering/absorption Small animal;
human breast and brain
Photoacoustic imaging [5] > 20mm <1mm
(detector bandwidth limited) Absorption Subsurface to deep imaging;
small animal; human breast
gold surface, and when the protein comes close enough for
binding, the hydrophobic pockets of the protein will make
contact and bind with the gold [24]. A general guideline to
optimize the bioconjugation is that the pH of the antibody
and the gold sol must be maintained at or slightly above the
isoelectric point of the antibody [24]. Following this, pro-
cedure for citrate-capped gold nanospheres with the HER81
antibody resulted in good bioconjugation as shown by the
spectroscopy and bioactivity studies (Figure 7).
With nanorods, the situation is more complex as com-
pared with nanospheres. The sidewalls of the nanorods
are expected to be stabilized with a bilayer of CTAB,
which imparts a positive charge to the gold. Huang
et al. [25] ﬁrst changed the positively charged surface
to a negatively charged one by exposing the nanorods
to poly(styrenesulfonate) PSS polyelectrolyte solution. The
PSS-cappednanorodswerethentreatedinthesamewayasin
Section 2.3 with the conjugation being done with anti-EGFR
monoclonal antibodies.
Zeta potentials of the gold nanorod solution as origi-
nally prepared were determined to be +55mV. Centrifuga-
tion to remove the excess unbound CTAB and redispersion
of the rods in water saw a reduction in the zeta potential to
+7.5mV,whichalsopointstoalowstability.Wesurmisethat
inspite of the net positive charge, the unpassivated end faces
would be negatively charged due to the presence of AuCl−2
ions [21]. We therefore performed the same protocol (as in
Section 2.3) and found that the bioconjugation indeed was
achieved as demonstrated by the red-shifted extinction spec-
tra as seen in Figure 6. Further, confocal microscopy success-
fully detected the bioconjugates on the HER2 positive cell
line (Figure 8), indicating the success of the conjugation.
Webelievethatthemechanismofconjugationisthesame
as that in the case of gold nanospheres that is electrostatic
and hydrophobic physisorption. It is also likely that at the
pH at which the antibody is maintained, the Fc fragment of
the antibody that is rich in positively charged amino acids
such as lysine will bind to the negatively charged chloride ion
layer on the exposed end faces of the rods. We intend to per-
form studies that will elucidate this aspect. Further, we will
perform the protocol of ﬁrst capping the nanorods with PSS
forexample,andthencomparingtheantigenbindingaﬃnity
constants of the bioconjugates from the two methods.
4.3. Potentialcontrastenhancingapplications
The scattering and absorption bands of the synthesized
nanorods span the wavelength regime between 675–850nm
that is of interest to optical imaging. This occupies the most
important part of the “optical imaging window” where lightRaja Gopal Rayavarapu et al. 9
penetration in tissue is high due to reduced scattering and
absorptioncoeﬃcients.Opticalimagingtechniques(Table 2)
that rely on scattering and/or absorption contrast to de-
tect pathological tissue could beneﬁt from the use of such
nanoparticles with or without targeting capability.
Our goal is to employ these particles as contrast agents
for photoacoustic cancer imaging, which has been proposed
earlier by Oraevsky and coworkers [26, 27]. Photoacoustic
imaging relies on optical absorption for its signals. When
photons are absorbed, nonradiative de-excitation of the ab-
sorbed optical energy takes place with the release of local-
ized heat. The local thermal expansion that results produces
pressure transients [5]. When illuminated with pulsed laser
light, a tumor site by virtue of its higher absorption with
respect to the healthy background tissue, due to angiogen-
esis [28], will act as a source of bipolar photoacoustic pulses.
This ultrasound propagates with minimal distortion to the
surface where it is detected using appropriate wideband de-
tectors.Thetime-of-ﬂight,amplitude,andpeak-peaktimeof
the bipolar PA pulse possess information regarding the loca-
tion, absorption, and dimensions of the source, thereby per-
mitting a reconstruction of the tumor site [29, 30].
It is known that the NIR optical absorption contrast of
tumors versus healthy tissue, measured using optical mam-
mographic methods, is between 1.5 and 3. Clinical trials of
optical mammography are being conducted worldwide but
at present, it seems implausible that intrinsic contrast alone
willprovidesuﬃcient sensitivity and speciﬁcity, and targeted
contrast enhancement is likely to be required [31]. Since the
same contrast mechanism of optical absorption is operative
in photoacoustic imaging as well, a similar conclusion may
be anticipated.
An impression of the feasibility of using the nanorods
synthesized for contrast enhancement is now discussed. The
absorption cross-section of a nanorod at a wavelength, say
800nm, is estimated using discrete dipole approximation
(DDSCAT) simulations [32, 33]a sCabs = 2.8 × 10−14 m2.A
typical average optical absorption coeﬃcient for an invasive
ductal carcinoma is μa = 0.008mm−1 at 800nm. In order to
achieve contrast enhancement, a certain number density of
gold nanorods is required to exhibit higher absorption than
the intrinsic value and may be calculated as
ρNR ≥
μa
Cabs
. (1)
This gives ρNR = 2.8 × 108 NR/cm3. Further photoacoustic
signals can be enhanced by a thermal nonlinearity mecha-
nism to 3 orders of magnitude higher [34], then the mod-
iﬁed number density of nanorods required is only ρNR =
2.8 ×105 NR/cm3.
Published studies report that most tumour cell types
express from 2 × 104 to 20 × 104 ErbB2 receptors/cell
[12]. Let us assume arbitrarily that 2 × 103 of these sites
per cell are occupied by conjugated nanorods. Further, if
we assume that 1% of cells at a tumor site overexpress
HER2 results in a ﬁgure of 2 × 106 cancer cells/cm3. This
will then lead to an estimation of the density of bind-
ing sites of the order of 109 cm−3. Comparison of ρNR
and the estimated ﬁgure of density of binding sites leads
us to believe that contrast enhancement will be possi-
ble.
We intend to test these molecular probes in small animal
photoacoustic imaging. Contrast enhancement with untar-
geted PEG-coated nanoparticles will be studied. Accumula-
tion of the contrast agent at the tumor site will depend on
enhanced permeation and retention (EPR). Active targeted
studies will follow, with conjugated nanoparticles adminis-
tered to the animal via the tail vein. In all studies, empha-
sis will be on ascertaining the sensitivity/eﬃcacy of the tech-
nique with and without contrast agent.
5. CONCLUSIONS
We have synthesized gold nanorods with optical extinction
peaks in the region from 675–850nm making these emi-
nentlysuitedforscatteringandabsorptioncontrastenhance-
ments in optical imaging. We have performed bioconjuga-
tion of these nanorods with HER81 antibodies, which bind
with high eﬃciency to HER2 receptors expressed by SKBR3
breast carcinoma cells. We demonstrated in ﬁxed cell stud-
ies that the targeting functionality of the antibody moiety re-
mains viable. However, it must be mentioned that the situa-
tioninvivowillbecomplexcomparedtothesimpliﬁedsitua-
tion in vitro. Other unresolved issues remain at present. One
of these is regarding toxicity and cellular uptake of these par-
ticles in vivo. Further, whether these molecular probes will
be able to extravasate into the tumor tissue through leaks
in the vasculature has not yet been studied. These are some
lines of research that we intend to follow in the near fu-
ture.
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